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non-adherence in patients with cardiovascular diseases and improve patient’s adherence to their
cardiovascular medications.Methods: In this prospective interventional study, we recruited patients
(n= 300) with cardiovascular diseases from three family medicine clinics in Al Ain, UAE in 2010.
We assessed patients’ responses to a validated brief medication questionnaire (BMQ). Results: At
the end of the study, we observed a signiﬁcant improvement in adherence. When we compared
pre- and post-interventions, the mean (± standard deviation, SD) score for non-adherence to cur-
rent regimen were 4.1 ± 0.2 vs. 3.0 ± 0.3 (p= 0.034); indication of negative believes or motiva-
tional barriers scores was 1.8 ± 0.4 vs. 0.9 ± 0.1 (p= 0.027); the indication of recall barrier
scores was 1.6 ± 0.1 vs. 0.8 ± 0.1 (p= 0.014); and the indication of access barrier scores was
1.6 ± 0.2 vs. 0.7 ± 0.2 (p= 0.019). Mean blood pressure, fasting blood glucose, glycosylated
hemoglobin, low density lipoprotein and postprandial blood glucose decreased signiﬁcantly
(p< 0.01) post-intervention. Conclusion: We reported that implemented multifaceted tools target-
ing patients, provider and healthcare system have improved the adherence to cardiovascular med-
ications. Our interventions managed to improve patients’ clinical outcome via improving adherence
to prescribed cardiovascular medications.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
‘‘Cardiovascular disease (CVD)’’ is an umbrella term referring
to any disease affecting the heart and blood vessels. These dis-
eases include hypertension, heart failure, coronary heart dis-
eases and stroke. CVDs remain paramount cause of
mortality globally (World Health Organization, 2003).
Several risk factors, including physiological, psychological,
behavioral and social habits, are associated with CVDs.
Hypertension remains the major risk factor associated with a
progressive rise of blood pressure, myocardial infarction
(MI), heart failure, chronic kidney disease, cognitive decline
and premature death. Hence, the cardiovascular drugs are cur-
rently the most used group of drugs in the geriatric
populations.
A major challenge in treating CVD is patients’ lack of
understanding of their health condition and adherence to the
treatment. Besides, patients are resistant to modify their life-
style and pharmacological regime that further leads to the
development of vascular diseases, (Al-Qasem et al., 2011).
Therefore, adherence describes all behaviors inﬂuencing
patients’ outcomes, such as medication-taking behavior, fol-
lowing dietary and lifestyle advice, vaccinations and obeying
follow-up visits (LaFleur and Oderda, 2004; Osterberg and
Blaschke, 2005; Munger et al., 2007; Corrao et al., 2008;
Thom et al., 2006). The additional term persistence is applied
to describe the duration of time from initiation to discontinua-
tion of drug therapy. Adherence and persistence are classiﬁed
as two dimensions of medication-taking behavior.
Non-adherence can indicate a variety of conditions, such as
not following the prescribed medical plan in general or can be
related to non-adherence with medications, diet, medical
appointments or refusal to stop a dangerous habit (smoking,
illicit drug or alcohol use). WHO stated that treatment non-ad-
herence is as a major public health problem that may result in
disease persistence (Rasmussen et al., 2007). A report by WHO
estimated that average rate of adherence to medication is
around 50% among patients suffering from chronic diseases
in developed countries and it is assumed to be lower in devel-
oping countries (World Health Organization, 2003). A recent
review conﬁrmed the existence of non-adherence to medicationas a serious problem among patients with chronic diseases in
the Middle East (Jackevicius et al., 2002). However, reported
rates of non-adherence varied greatly, probably due to
differences in deﬁnitions, measuring tools, study population,
study design and predictors of adherence/non-adherence.
Some barriers and predictors of non-adherence among patients
in Middle East region were identiﬁed. However, the 19 studies
included in this review did not provide consequential
conclusions regarding the level of adherence (Jackevicius
et al., 2002). Hence, there is need for further research on the
prevalence of non-adherence and barriers to medication adher-
ence in order to identify type of interventions needed to
improve treatment adherence, particularly in patients with
complex chronic diseases.
On average, approximately half of patients do not adhere
to prescribed treatment regimens (Beardon et al., 1993).
Studies have shown that poor adherence to beta-blockers or
statin in post-MI patients can lead to an increased risk of
morbidity and mortality (Kirking et al., 1995; Fincham and
Wertheimer, 1988). After MI, several strategies including early
follow up and sending printed reminders to patients were
proposed to improve adherence (Jackevicius et al., 2002).
Studies on non-adherence found that 1–21% of prescriptions
were unﬁlled or not claimed from hospital pharmacies
(Craghead and Wartski, 1991; Skutnik and Katsanis, 1997).
In other studies, non-adherence to medications has been
shown to increase mortality and hospitalizations (Jackevicius
et al., 2007; Jackevicius et al., 2008).
The issue of adherence to cardiovascular medications is
unique as most patients with CVDs were concomitantly
having co-morbid conditions with evident poly-pharmacy.
The problem of non-adherence to cardiovascular medications
is of particular interest as it has direct impact on the disease
management, prognosis and patient’s quality of life.
Medication adherence is not part of the electronic system
neither incorporated in daily routine care in the United
Arab Emirates (UAE).
To our knowledge, there is no any study which may provide
insights on the adherence to cardiovascular medications in
UAE. In the absence of relevant literature in our region, we
aimed to conduct a study on the adherence of patients to
Table 1 Patient proﬁle (survey respondents’) with and without adherence to cardiovascular medications.
Parameter *F, (%) Adherence P value
Good score Poor score
Age groups, [mean age 53 ± 2.1(years)]
20 – 49 142 (47.3) 93 || (65.5) 49 (34.5)
50 – 79 158 (52.7) 89 || (56.3) 69 (43.7)
Subtotal (at each parameter subrows) 300 (100.0) 182 || (60.7) 118 (39.3) 0.002
Gender
Male [mean age 51 ± 1.6 (years)] 146 (48.7) 91 || (62.3) 55 (37.7)
Female [mean age 49 ± 1.7(years)] 154 (51.3) 101 || (65.6) 53 (34.4)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) §0.057
Education
School education 161 (53.7) 91|| (56.5) 70 (43.5)
University and post university 139 (46.3) 101 || (72.7) 38 (27.3)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) 0.037
Marital status
Married 266*(88.7) 163 || (61.3) 103 (38.7)
Single 34 (11.3) 29 || (70.6) 5 (29.4)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) 0.002
BMI (kg/m2)
Normal weight 6 25 62 (20.6) 43 || (69.4) 19 (30.6)
Over weight > 25 to <30 170 (56.7) 103 || (60.6) 67 (39.4)
Obese > 30 68 (22.7) 46 || (67.6) 22 (32.4)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) 0.001
Disease type [duration of disease in years (7 ± 3.1)]
Diabetes 58 (19.3) 37 || (63.8) 21 (36.2)
Hypertension, diabetes, and CVD 71 (23.7) 43 || (60.6) 28 (39.4)
Hypertension 78 (26.0) 47 || (60.2) 31 (39.8)
Hypertension and diabetes 93 (31.0) 65 || (69.9) 28 (30.1)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) 0.007
Monthly income
<2900 US $ (<10, 000 Dirham) 53 (17.6) 20 (37.7) 33 || (62.3)
2900–6000 US $ (10, 000 – 22,000 Dirham) 119(39.7) 85 || (71.4) 34 (28.6)
6000 US $ (> 22, 000 Dirham) 128*(42.7) 87 ||(67.9) 41 (32.1)
Subtotal (at each parameter subrows) 300 (100.0) 192 || (64.0) 108 (36.0) 0.012
Key:
* F=Frequency.
 (%) = percentage.
 p< 0.05.
§ p> 0.05, || the highest percentage achieved in subrows, items within each scale were averaged after scoring.
184 A. Shehab et al.cardiovascular medications and to intervene to the adherence
of patients by improving patients’ negative beliefs, motiva-
tional barriers, indication of recall barrier and indication of
access barrier to adherence and the pattern of sustained
improvement throughout the study period. Furthermore, we
aimed to implement behavioral and educational tools that
improve patient’s adherence to their cardiovascular
medications.
2. Methods
2.1. Ethics
The Al-Ain Medical District Human Research Ethics
Committee (AMDHREC) has approved the study protocol.
All subjects read the study information sheet and signed the
informed consent prior to participation.2.2. Study design
The cross-sectional study was performed in three main Family
Medicine Clinics (FMCs) in downtown in 2010. These FMCs
were specialized on chronic diseases such as CVDs and
diabetes. Patients were randomly selected from clinic chronic
disease database, whereby; legible candidates were invited to
join the study. The FMCs have standardized registry for
patients with chronic diseases. We used this registry to select
patients with CVDs, diabetes and poly-pharmacy. Patients of
both genders with UAE nationality, over 20 years of age, with
CVD diagnosis over 3 months, taking 4 or more medications
for CVDs (4 corresponds to the mean number of prescribed
drugs in cardiology and medical clinic in Al Ain hospital, Al
Ain-UAE) were included in the study (Elnour et al., 2008;
Andrew et al., 2003). Pregnant women, patients with debilitat-
ing diseases were excluded from the study.
Table 2 Brief Medication Questionnaire (BMQ) scale scores.
Assessment interval ﬁ
Scale parameter
Question as
per BMQ
Appendix
A
Total
score
of
items
Mean
score
baseline
Mean score
at 3 months
Mean score
at 6 months
Mean score
at 9 months
Mean score
at 12 months
p value
(Post
hoc)
A. Indication of non-adherence
with current drug regimen
Questions
1a to 1e
5 4.1 ± 0.2 3.9 ± 0.2 3.6 ± 0.3 3.1 ± 0.4 3.0 ± 0.3 0.034
B. Indication of negative
beliefs or motivational barriers
Questions
1 g, and 2a
2 1.8 ± 0.4 1.7 ± 0.5 1.4 ± 0.2 1.2 ± 0.4 0.9 ± 0.1 0.027
C. Indication of recall barrier Questions
1c and 3b
2 1.6 ± 0.1 1.6 ± 0.1 1.4 ± 0.2 1.0 ± 0.3 0.8 ± 0.1 0.014
D. Indication of access barrier Questions
3c and 3e
2 1.6 ± 0.2 1.5 ± 0.1 1.2 ± 0.2 0.8 ± 0.3 0.7 ± 0.2 0.019
Key: The values of p compared baseline data with post-interventions data (at 3, 6, 9 and 12 months); B= regarding efﬁcacy, bothersome side
effects, other concerns regarding a given drug and its effects. C. Indication of recall barrier = about potential difﬁculties remembering. D.
Indication of access barrier = 1. Report any difﬁculty paying for medications 2. Report any difﬁculty getting reﬁlls in time.
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for the chronic diseases management strategy. We stratiﬁed
patients considering the duration of drug treatment and
number of years since diagnosis of CVDs. We utilized a
calculation method to draw a reasonable sample for our pop-
ulation. We used 90% conﬁdence level (90% actual mean falls
within our conﬁdence interval), 0.5 standard deviation
(expected variance), and a margin of error (conﬁdence interval)
of ±5% (higher or lower than population mean our sample
mean may fall). 90% – Z Score = 1.645; (1.645)2 · 0.5(0.5)/
(0.05)2, (2.7 · 0.25)/0.0025 = 270. The needed sample size
was estimated to be 270; however, we have increased this to
300 patients to allow for any dropouts. Therefore, we have
recruited patients with CVDs (n= 300) from three FMCs in
Al Ain city, UAE. These patients were prospectively followed
for one year and data were reported for every patient at 3, 6, 9
and 12 months.
Patients’ responses were assessed with a validated brief
medication questionnaire (BMQ). Additionally, fasting blood
glucose (FBG), postprandial blood glucose (PPBG), glycosy-
lated hemoglobin (HbA1c), low density lipoprotein (LDL)
and blood pressure (BP) were measured before and after the
interventions. Baseline qualitative and quantitative data were
collected for each patient from their medical ﬁles and via the
questionnaires. Baseline assessment involved evaluation of
each patient’s BMQ. The baseline characteristics of the study
population involved the identiﬁcation and numbering of pre-
scribed cardiovascular drugs. Patients were taking multiple
numbers and doses of cardiovascular drugs for years. They
did not receive any form of medication adherence advice,
nor were examined for non-adherence.
2.3. The educational and behavioral interventions
The conceptual frame work of the interventions was extrapo-
lated from the theory of planned behavior (TPB) with more
integration of health belief model. The educational and
behavioral tools have targeted patient’s (health literacy, educa-
tion, complexity of medications and socioeconomic status),
health professional’s (communication skills and behavioralsupport) and the healthcare system (practice environment,
pharmacy ordering and reﬁll system, access, educational
materials and electronic health record). The interventions plan
(clinical guidelines, information system, and team work) was
introduced in one month after baseline (interventions), and
thereafter reinforced once every three months for one year
(Appendix A).
2.4. Brief medication questionnaire (BMQ) validity
The BMQ is a self-reporting tool used to identify patients at
risk of non-adherence. In our study we used validated BMQ
tool to assess adherence to cardiovascular medications,
(Cherry et al., 2008). The tool includes a ‘‘5-Item Regimen
Screen’’ (Appendix B) that asks patients how they took each
medication in the past week, a ‘‘2-Item Belief Screen’’ that asks
about drug effects and bother some features, and a ‘‘2-item
Recall Screen’’ about potential remembering difﬁculties.
Validity of the BMQ has been previously tested (Svarstad
et al., 1999). The adherence risk score (ARS) measures the
number of present adherence risk factors and is constructed
by adding the subtotals listed above (Subtotal A + Subtotal
B + Subtotal C + Subtotal D = ARS) (Cherry et al., 2008).
The ARS ranges from 0 to 4, with ‘‘0’’ indicating non-self-re-
ported non-adherence or barriers to adherence and ‘‘4’’ indi-
cating presence of self-reported non-adherence and three
types of barriers (Belief or Motivational barrier, Recall barrier,
and Access barrier). The original English version of BMQ was
translated into Arabic language, piloted and tested for
psychometric component and the Cronback Alpha was found
to be 0.73. An ofﬁcial written permission for using the BMQ
was obtained from the original BMQ authors (Svarstad
et al., 1999).
2.5. Outcome measures
The primary outcome was the improvement in responses to
BMQ scores (at 3, 6, 9 and 12 months after the interventions).
The secondary outcomes were disease-related as fasting blood
glucose (FBG), postprandial blood glucose (PPBG), glycated
Table 3 Medications and clinical parameters.
Parameter *F, (%) Adherence P Value
Good (score) Poor (score)
Drug classes *F, (%) *F, (%)
Cardiovascular medications 300 (100.0) 233|| (77.7) 67 (22.3) 0.003
Antidiabetic medications 58 (19.3) 37|| (63.8) 21 (36.2) 0.049
Statins 213 110|| (51.6) 103 (48.4) 0.032
Fasting Blood Glucose Mean ± SD
[Baseline 10.6 lmol/L to 8.0 lmol/L at 12 months]
300 (100.0) 178|| (59.3) 122 (40.7) 0.01
Post-prandial blood glucose Mean ± SD
[Baseline 11.4 ± 0.6 lmol/L to 8.6 ± 0.5 lmol/L at 12 months]
300 (100.0) 183|| (61.0) 117 (39.0) 0.006
Glycosylated hemoglobin Mean ± SD
[Baseline 8.9 ± 0.3% to 7.4 ± 0.4% at 12 months]
300 (100.0) 194|| (64.7) 106 (35.3) 0.02
Low Density Lipoprotein Mean ± SD
[Baseline 3.1 ± 0.04 lmol/L to 2.7 ± 0.01; at 12 months]
300 (100.0) 169|| (56.3) 131 (43.7) 0.002
Systolic BP (mmHg) Mean ± SD
[Baseline 143.0 ±15.0 mmHg to 132 ± 10.7 mmHg at 12 months]
300 (100.0) 216|| (72.0) 84 (28.0) 0.027
Diastolic BP (mmHg) Mean ± SD
[Baseline 97.0 ±12.0 mmHg to 83 ± 8.7 mmHg at 12 months]
300 (100.0) 207|| (69.0) 93 (31.0) 0.023
Target blood pressure =<130/80 mmHg for people with diabetes.
§ p> 0.05, ||the highest percentage achieved in subrows, items within each scale were averaged after scoring.
Key:
* F = Frequency.
 (%) = percentage.
 p< 0.05.
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(LDL-C) and blood pressure (BP).
2.6. Data analysis
Data analysis was carried out using the Statistical Package for
Social Sciences, version 20 (SPSS Inc., Cary, NC, USA). Data
were presented as proportions, means with standard devia-
tions (±SDs) when appropriate. Differences in categorical
variables within respective comparison age and gender groups
and poor vs. good adherence were analyzed using chi-squared
test. The continuous variables (FBG, PPBG, HbA1c, LDL-C
and BP) were analyzed using one way analysis of variance.
The BMQ scores at the different assessment intervals were
analyzed by using chi-squared test. We performed regression
analysis (signiﬁcance was by F-test, followed by t-tests of
individual important parameters) to identify the variable
relationship (adherence ARS) with non-adherence to cardio-
vascular medications. P values <0.05 were considered
signiﬁcant.
3. Results
We did not experience any dropouts through the study. The
demographic and anthropometric characteristics of the
participants were shown in Table 1. The mean age was
53 ± 2.1 years. For the subjects with or without multiple
cardiovascular risk factors adequate adherence was found to
be 69.9% and 30.1%, respectively. The correlation between
adherence and patient’s income was statistically signiﬁcant
among intermediate and high income patients. However, no
such relation was documented in low income patients
(Table 1).3.1. Indication of non-adherence with current drug regimen
3.1.1. Brief medication questionnaire (BMQ)
BMQ scale mean scores (±SD) at baseline (total scores = 5.0)
have revealed positive indication of non-adherence with car-
diovascular medications as indicated by mean score of
4.1 ± 0.2. The reasons for this nonadherence were as follows
(in descending order): missed dose/doses, missed day(s),
patient failed to mention or list their prescribed drug(s) and
patient stopped or interrupted treatment for different reasons
(Table 2). The adherence risk score (ARS) yielded an estimate
of 3.1 ± 0.2 for the number of adherence risk factors present
which indicated the presence of self-reported non-adherence
and three types of barriers (Belief or Motivational barrier,
Recall barrier, and Access barrier). However, after
interventions the ARS mean scores improved over time for
the different assessment periods: 2.9 ± 0.1, 2.4 ± 0.1,
1.8 ± 0.1 and 1.4 ± 0.2 at 3, 6, 9, and 12 months; respectively.
The screen of indication of negative beliefs or motivational
barriers to adherence was represented by efﬁcacy, bothersome
side effects, other concerns regarding a given drug and its
effects (total scores = 2.0) and was reported at baseline with
mean scores (1.8 ± 0.4), (Table 2). The indication of ‘‘Recall
barrier’’ was addressed using two questions: whether patient
received multiple doses regimen (2 or more times/day) and/or
reports any difﬁculty remembering his/her medications.
Indication of ‘‘Recall barrier’’ (total scores = 2.0) was
reported at baseline with mean scores (1.6 ± 0.1), which have
indicated the presence of Recall barriers (Table 2).
In order to address ‘‘Access barrier’’, we have used two
questions:1. Report any difﬁculty paying for medications 2.
Report any difﬁculty getting reﬁlls in time. Indication of
Access barrier (total scores = 2.0) was reported at baseline
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presence of Access barriers (difﬁculty paying for medications)
as hindrance to adherence to cardiovascular medications
(Table 2). After interventions, the mean scores on this domain
improved over time for the different assessment periods:
1.5 ± 0.1, 1.2 ± 0.2, 0.8 ± 0.3 and 0.7 ± 0.2 at 3, 6, 9 and
12 months, respectively (Table 3).4. Discussion
Cardiovascular diseases and hypertension are associated with
enormous economic and personal burden through increased
risk of stroke and kidney disease (Cherry et al., 2008; James
et al., 2014; Go et al., 2013). The treatment of CVDs has been
unequivocally shown to positively impact patient-related
outcomes leading to reductions in stroke and heart failure
(Chobanian et al., 2003).
In the current study, the predicting and estimated risk
factors for non-adherence to prescribed cardiovascular
medications were identiﬁed. Considering gender, our results
indicated that males were less compliant with cardiovascular
medications than females (Wang et al., 2005).Besides,
education and high income also provide good adherence to
drug regimens.
In patients who are treated with cardiovascular drug
regimens, we have identiﬁed contributory factors to non-
adherence as missed treatment doses or day(s), failure to
report non-adherence, or interrupted treatment regimens.
Besides, we have found 40% more adherence in patients over
65 years as compared to those under 65 years, which was in
contrast to the study by Monane et al., (1996).
Healthcare professionals have to shorten regimens where
possible (Murphy et al., 2003; Black, 1999). Besides, they must
educate their patients about the signiﬁcance of adhering to
their prescribed regimens. In accordance with currently
available evidence, our ﬁndings highlighted that some patients
lack medication knowledge and this is the major cause for
poor adherence (Mini et al., 2012). In general, poly-pharmacy
has major impact on adherence to cardiovascular medications
(Stone et al., 2001; Golin et al., 2002) and the most frequent
reason for non-adherence was multiple medications (poly-
pharmacy) herein. Our current interventions succeeded in
weaning patients’ negative beliefs, improving motivational
barriers, indication of recall barrier and indication of access
barrier to adherence and the improvement was sustained
throughout the study period.
A retrospective study reported that compared to concurrent
two-pill therapy single-pill combination therapy (contained in
one pill dosage form) provided 20% higher adherence and
more subjects from the single-pill combination therapy
continued to take prescribed medication for 12 months
(Dezii, 2000; Haynes et al., 2008). In an electronic monitoring
study conducted on 149 patients receiving cardiovascular med-
ications, only dosing frequency (p= 0.0001) but not drug class
(P= 0.71) was associated with medication adherence in the
adjusted analysis. The authors have suggested that providers
may consider using once daily formulations to optimize
adherence and should assess adherence among all treated
patients with uncontrolled hypertension (Moise et al., 2014).
Thus, a plausible strategy to improve adherence to medications
may include considering a combination single-pill therapywhere applicable. In another study conducted by Castellano
et al. (2014), the researchers suggested that use of a poly-pill
strategy met the primary end point for adherence for
secondary prevention following an acute MI (Castellano
et al., 2014a). This was also evident for present study patients
with poly-pharmacy and multiple adherence risk factors.
Major trials are being conducted and they will hopefully
provide deﬁnitive evidence on the efﬁcacy of the poly-pill in
reducing cardiovascular events in a cost-effective manner.
The results of these trials will determine whether a poly-pill
strategy can suppress the CVD pandemic and will potentially
provide the evidence to implement in cost-effective, easy,
simple, and innovative solution for the global burden of
CVDs (Castellano et al., 2014).
Another interesting ﬁnding in our study was a remarkable
decrease in mean values of FBG, PPBG, HbA1c, LDL and
BP, which may be attributable to the interventions and the
strict follow up of patient’s adherence issues throughout the
study period. Therefore, patients with CVDs should also be
informed particularly by their pharmacists that adherence can
improve speciﬁc blood markers for both for CVDs and diabetes.
The use of multifaceted approach comprising of
educational and behavioral tools to improve adherence to car-
diovascular medications was applied in the present study.
Another important point is that the prospective follow up of
patients and enforcement of successive structured interven-
tions were succeeded in patients who were not adhering to
cardiovascular medications. Besides, subsequent respective
measures were deployed. However, our sample population
may not be representative of general practitioner clinics and
rather more like the specialized clinics as it is drawn from
FMC targeting only patients with CVDs.
In conclusion, the study outcomes have direct inﬂuence on
health policy, medication safety practices and clinical out-
comes of patients with CVDs. The behavioral and educational
interventions deployed in this study can be friendly used by
healthcare providers in UAE and in similar settings for further
improving adherence to cardiovascular medications. Similar
studies with higher number of randomized subjects are needed
to improve patient adherence in Middle East, particularly in
UAE.Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.jsps.2015.
02.022.
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